Customized Marketing Strategies for Cancer Immunocyte Therapy Based on its Distinctive Attributes

Xiaojing Liu,1 Chen Wei,1 Xinbin Han,1 Wei Pan,2 Jing Lv3 1Department of Marketing, School of Economics and Management, Qingdao Institute of Technology, Qingdao, Shandong, 266300, People’s Republic of China; 2Department of Business Administration, School of Economics and Management, Qingdao Institute of Technology, Qingdao, Shandong, 266300, People’s Republic of China; 3Department of Logistics Management, School of Economics and Management, Qingdao Institute of Technology, Qingdao, Shandong, 266300, People’s Republic of ChinaCorrespondence: Xiaojing Liu, Department of Marketing, School of Economics and Management, Qingdao Institute of Technology, 236 Fuzhou South Road, Jiaozhou, Qingdao, Shandong, 266300, People’s Republic of China, Email [email protected]: Cancer constitutes a persistent global health challenge, and immunocyte therapy has emerged as one approach in oncological care. This narrative review aimed to systematically analyze, synthesize, and critically interpret the therapeutic characteristics, advantages, market landscape, and current access barriers of cancer immunocyte therapy, based on thematic clustering and cross‑study integration of clinical evidence, market data, and industry reports. Immunocyte therapy exhibits distinctive features including personalization, long‑term immune memory, and observed efficacy in refractory malignancies, yet its clinical accessibility is limited by high costs, low public and physician awareness, and unsuitable traditional marketing models. Through thematic synthesis and pattern identification across included studies, this review identified core strategic directions including precise hierarchical positioning, academic and digital medical education, innovative payment models, industrial-chain integration, data‑driven dynamic optimization, policy leverage, and differentiated product‑service strategies. Each strategy is supplemented with comprehensive implementation feasibility analysis, covering regulatory constraints, infrastructure limitations, cost implications, stakeholder barriers, and context‑dependent variability to enhance practicality and credibility. These tailored marketing approaches are associated with improved market penetration, expanded patient access, and potential support for the clinical and commercial value of immunocyte therapy. This review provides evidence‑based, analytically integrated strategic insights for enterprises, medical institutions, and policymakers to promote the rational commercialization and equitable access of cancer immunocyte therapy.Keywords: cancer therapy, immunocyte therapy, personalized medicine, marketing  strategies, market accessibility, cost-effectiveness